Background: Malignant mixed Müllerian tumors (MMMTs) are aggressive tumors arising in the female lower genital tract and characterized by the presence of both a malignant epithelial and a mesenchymal component. Here, we report a case of an MMMT of the uterine corpus with an extensive squamous-cell carcinomatous component processed by liquid-based cytology (LBC). Case Report: An 84-year-old woman with a prior history of anal squamous-cell carcinoma, who complained of vaginal bleeding, was discovered to have a mass protruding from the uterine cervix. A Papanicolaou (Pap) test was performed and the LBC (ThinPrep) preparation showed a background of neutrophils and cellular debris. Atypical cells were identified that presented with hyperchromatic nuclei, nuclear membrane irregularities, multinucleation and abundant cytoplasm with focal keratinization. Scattered nucleolated malignant elements were also identified. The cytological diagnosis resulted in ‘suspicious for squamous-cell carcinoma', favoring primary cervical carcinoma rather than extracervical (anal) carcinoma. The histological examination showed that it was an MMMT with an extensive squamous-cell carcinomatous component. Conclusion: This case illustrates the potential diagnostic pitfall of MMMTs with extensive squamous-cell carcinomatous components in LBC Pap smears. Cytopathologists should keep in mind this diagnostic possibility in postmenopausal women who experience vaginal bleeding or spotting.

Keywords:
Papanicolaou smear, Liquid-based cytology, Malignant mixed Müllerian tumor
1.
D'Angelo E, Prat J: Pathology of mixed Müllerian tumours. Best Pract Res Clin Obstet Gynaecol 2011;25:705-718.
2.
Kanthan R, Senger JL: Uterine carcinosarcomas (malignant mixed müllerian tumours): a review with special emphasis on the controversies in management. Obstet Gynecol Int 2011;2011:470795.
3.
El-Nashar SA, Mariani A: Uterine carcinosarcoma. Clin Obstet Gynecol 2011;54:292-304.
4.
Costa MJ, Tidd C, Willis D: Cervicovaginal cytology in carcinosarcoma [malignant mixed mullerian (mesodermal) tumor] of the uterus. Diagn Cytopathol 1992;8:33-40.
5.
Massoni EA, Hajdu SI: Cytology of primary and metastatic uterine sarcomas. Acta Cytol 1984;28:93-100.
6.
Oda T, Shimazaki H, Takahashi H, Endo H, Sekitsuka K, Maekawa K, Katsurada Y, Kono T, Ueno H, Takano M, Nakanishi K, Tamai S: Immunocytochemistry of mesenteric malignant mixed müllerian tumor in peritoneal effusion cytology: case report. Cytopathology 2012;23:334-337.
7.
An-Foraker SH, Kawada CY: Cytodiagnosis of endometrial malignant mixed mesodermal tumor. Acta Cytol 1985;29:137-141.
8.
Kanbour AI, Buchsbaum HJ, Hall A, Kanbour AI: Peritoneal cytology in malignant mixed müllerian tumors of the uterus. Gynecol Oncol 1989;33:91-95.
9.
Banik T, Halder D, Gupta N, Dey P: Malignant mixed Müllerian tumor of the uterus: diagnosis of a case by fine-needle aspiration cytology and review of literature. Diagn Cytopathol 2012;40:653-657.
10.
Khalbuss WE, Pantanowitz L, Monaco SE: Cytomorphology of unusual primary tumors in the Pap test. Cytojournal 2013;10:17.
11.
Gupta N, Dudding N, Smith JH: Eight cases of malignant mixed Müllerian tumor (carcinosarcoma) of the uterus: findings in SurePath™ cervical cytology. Diagn Cytopathol 2014;42:165-169.
12.
Kernochan LE, Garcia RL: Carcinosarcomas (malignant mixed Müllerian tumor) of the uterus: advances in elucidation of biologic and clinical characteristics. J Natl Compr Canc Netw 2009;7:550-556.
13.
Ahuja A, Safaya R, Prakash G, Kumar L, Shukla NK: Primary mixed mullerian tumor of the vagina - a case report with review of the literature. Pathol Res Pract 2011;207:253-255.
14.
McCluggage WG: Mullerian adenosarcoma of the female genital tract. Adv Anat Pathol 2010;17:122-129.
15.
Lee SH, Kim J, Kim JH, Lee KH, Park JS, Hur SY: Malignant mixed mullerian tumor of the cervix including components of a rhabdomyosarcoma: case report and literature review. Eur J Gynaecol Oncol 2010;31:462-466.
16.
Kuyumcuoglu U, Kale A: Homologous type of malignant mixed Mullerian tumor of the uterus presenting as a cervical mass. J Chin Med Assoc 2009;72:533-535.
17.
Horn LC, Dallacker M, Bilek K: Carcinosarcomas (malignant mixed Mullerian tumors) of the uterus. Morphology, pathogenetic aspects and prognostic factors (in German). Pathologe 2009;30:292-301.
18.
Snyder RR, Norris HJ, Tavassoli F: Endometrioid proliferative and low malignant potential tumors of the ovary. A clinicopathologic study of 46 cases. Am J Surg Pathol 1988;12:661-671.
19.
Clement PB, Zubovits JT, Young RH, Scully RE: Malignant mullerian mixed tumors of the uterine cervix: a report of nine cases of a neoplasm with morphology often different from its counterpart in the corpus. Int J Gynecol Pathol 1998;17:211-222.
20.
Casey MB, Caudill JL, Salomão DR: Cervicovaginal (Papanicolaou) smear findings in patients with malignant mixed Müllerian tumors. Diagn Cytopathol 2003;28:245-249.
21.
Rossi ED, Raffaelli M, Zannoni GF, Pontecorvi A, Mulè A, Callà C, Lombardi CP, Fadda G: Diagnostic efficacy of conventional as compared to liquid-based cytology in thyroid lesions: evaluation of 10,360 fine needle aspiration cytology cases. Acta Cytol 2009;53:659-666.
22.
Gibb RK, Martens MG: The impact of liquid-based cytology in decreasing the incidence of cervical cancer. Rev Obstet Gynecol 2011;4(suppl 1):S2-S11.
23.
Smith JH: Cytology, liquid-based cytology and automation. Best Pract Res Clin Obstet Gynaecol 2011;25:585-596.
24.
Yoshida T, Sano T, Kanuma T, Inoue H, Itoh T, Yazaki C, Obara M, Fukuda T: Usefulness of CINtec® PLUS p16/Ki-67 double-staining in cytological screening of cervical cancer. Acta Cytol 2011;55:413-420.
25.
Byun SW, Lee A, Kim S, Choi YJ, Lee YS, Park JS: Immunostaining of p16(INK4a)/Ki-67 and L1 capsid protein on liquid-based cytology specimens obtained from ASC-H and LSIL-H cases. Int J Med Sci 2013;10:1602-1607.
26.
Song SH, Hong JH, Kwak SH, Lee JK, Kim MK: Clinical performance assessment of five human papillomavirus DNA tests using liquid-based cytology samples. J Obstet Gynaecol Res 2012;38:408-414.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.